[Kookmin Ilbo] February 6, 2018
High value-added new technologies are expected to receive attention during industrialization.
Stem cell specialist Miracell Co., Ltd. (CEO Shin Hyun-soon, pictured) announced on the 5th that it has successfully developed a blood-derived immune cell and stem cell treatment targeting colon cancer.
This treatment is made primarily from blood-derived immune cells and stem cells isolated and extracted using Miracell’s proprietary cell separation and concentration technology.
In vitro cell experiments verifying safety and efficacy demonstrated outstanding anticancer effects.
Shin Hyun-soon, CEO of Miracell, stated, “Because the treatment preparation period is very short, we expect this technology to gain recognition as a high-value-added new technology if commercialized.”
Miracell is also developing minimally invasive stem cell treatment separation and extraction technologies useful for treating cartilage regeneration, lower extremity ischemia, and myocardial infarction, and is currently pursuing marketing approval.
Medical Reporter Lee Ki-soo